Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function


∗These authors contributed equally to this work.

Congenital disorders of glycosylation are a growing group of rare genetic disorders caused by deficient protein and lipid glycosylation. Here, we report the clinical, biochemical, and molecular features of seven patients from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an O-linked glycosylation disorder. GALNT2 encodes the Golgi-localized polypeptide N-acetyl-D-galactosamine-transferase 2 isoenzyme. GALNT2 is widely expressed in most cell types and directs initiation of mucin-type protein O-glycosylation. All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2. Patients with GALNT2-CDG generally exhibit a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels. Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities. In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits, decreased sociability, and impaired sensory integration and processing. The multisystem nature of phenotypes in patients and rodent models of GALNT2-CDG suggest that there are multiple non-redundant protein substrates of GALNT2 in various tissues, including brain, which are critical to normal growth and development.

1 Department of Paediatrics, Danish Epilepsy Centre Filadelfia, 4293 Dianalund, Denmark
2 Department of Pediatrics, Division of Human Genetics, Section of Biochemical Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
3 Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
4 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
5 Medical Genetics Department, Bambino Gesù Children’s Hospital, 00146 Rome, Italy
6 Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo 12311, Egypt
7 Department of Paediatric Neurology, Children’s Hospital Datteln, Witten/Herdecke University, 45711 Datteln, Germany
8 Centre for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, 2650 Hvidovre, Denmark
9 Neurology Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, 00146 Rome, Italy
10 Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre Filadelfia, 4293 Dianalund, Denmark

Received August 27, 2019. Revised December 30, 2019. Accepted January 20, 2020
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For permissions, please email: journals.permissions@oup.com
Introduction

Congenital disorders of glycosylation (CDG) are a heterogeneous group of rare genetic disorders with a wide range of phenotypes. They arise from defects in protein, lipid or proteoglycan glycosylation pathways (Jaeken and Peanne, 2017). Deficiencies in glycosyltransferase genes are found to cause more than half of the some 130 reported CDG (Ng and Freeze, 2018).

Recently, deficiencies in glycosyltransferase genes of larger isoenzyme families have been shown to cause CDG with less severe clinical phenotypes (Joshi et al., 2018). Traditional biomarker assays, such as characterization of the N-glycosylation state of plasma transferrin (Wopereis et al., 2007), do not generally identify these newer CDG (Ng and Freeze, 2018). Discovering and validating such CDG, as well as identifying the molecular mechanisms underlying deficiencies in glycosylation that affect only a few proteins, remain challenging endeavours.

Mucin-type or N-acetyl-D-galactosamine (GalNAc)-type O-glycosylation is initiated by a large family of polypeptide GalNAc-transferase (GALNT, also known as GalNAc-T) isoenzymes with considerable overlapping functions in directing O-glycosylation of proteins. The GALNTs represent an emerging gene family where aberrant function of a single isoenzyme can result in extremely subtle loss of non-redundant glycosylation of one or few proteins and lead to CDG (Joshi et al., 2018). This was first realized with the discovery that pathogenic variants in GALNT3 caused familial tumoral calcinosis (Topaz et al., 2004). It was later demonstrated that pathogenesis of familial tumoral calcinosis is caused by highly specific loss of O-glycosylation at a single O-glycosite in phosphaturic factor fibroblast growth factor 23 (FGF23), which co-regulates biological activity and phosphate homeostasis (Kato et al., 2006).

As a member of the GALNT family, GALNT2, was initially implicated in human lipoprotein metabolism by genome-wide association studies (GWAS) (Kathiresan et al., 2008). Previously, we described two unrelated individuals with intellectual disability and biallelic variants in GALNT2 who had reduced levels of high-density lipoprotein cholesterol (HDL-C) and plasma triglycerides (Khetarpal et al., 2016). Unique protein substrates for the encoded GALNT2 included the lipoprotein lipase inhibitors angiopoietin-like 3 (ANGPTL3), apolipoprotein C-III (apoC-III) (Schjoldager et al., 2012), and phospholipid transfer protein (PLTP) (Khetarpal et al., 2016). Using these proteins as biomarkers,
we confirmed complete loss-of-function of GALNT2 in two unrelated individuals (Khetarpal et al., 2016). One of the two patients (c.865C>T; p.Gln289*) was separately reported to have a complex medical history with very severe intellectual disability, seizures, autism spectrum disorder, aggressive behaviour, feeding problems in infancy, short stature, constipation, strabismus, and inguinal hernia (Reuter et al., 2017). GALNT2 was suggested as a novel candidate gene, potentially explaining the observed neurodevelopmental disorder.

Here, we report three additional families with six previously unpublished individuals exhibiting biallelic pathogenic variants in GALNT2. We comprehensively describe the clinical, biochemical, and molecular characteristics of a total of seven patients with GALNT2-CDG. In particular, we confirm the loss of plasma apoC-III O-glycosylation as a robust biomarker assay for the disorder. Furthermore, we demonstrate that the physical and behavioural characteristics of rodent models of GALNT2-CDG with knockout of Galnt2 recapitulate many of the features seen in patients, including poor growth and neurodevelopmental and lipid abnormalities.

Patients and methods
This study was performed in accordance with ethical principles for medical research outlined in the Declaration of Helsinki. All relevant approvals from the institutional ethics committees of the participating institutions were obtained as well as written informed consent from all patients’ guardians before inclusion in the study.

Patients
We describe seven patients (Patients A–G) with biallelic pathogenic GALNT2 variants from four families (Families 1–4), including six previously unpublished patients. Patient A from Family 1 was previously published (Khetarpal et al., 2016; Reuter et al., 2017); the present study also included a younger affected brother (Patient B). Patients were recruited from research or diagnostic programs in Europe and the Arab Republic of Egypt. Grouping of clinical data for this series was facilitated by GeneMatcher (Sobreira et al., 2015). All patients were clinically evaluated by neuropediatricians and clinical geneticists at their respective tertiary healthcare centres. Patients underwent comprehensive history and physical examinations, fasting blood chemistry, genetic testing, EEG and brain MRI scan. EDTA plasma samples for western blot and mass spectrometry analysis were obtained by venepuncture, red cells were pelleted by centrifugation and plasma was separated, frozen and shipped on dry ice to the analysing laboratories. Various protocols were used to obtain brain MRI scans, which were of varying field strengths, slice thicknesses, and image qualities (3T DICOM format to 6 mm slice thickness hard copy film photos at 1.5 T). The same neuroradiologist evaluated all scans. In some patients, hand X-ray, echocardiography, and abdominal ultrasonography were also performed.

Growth analysis
Patient growth was evaluated utilizing the growth charts indicated in Table 2 and in the Supplementary material. Short stature was defined as length/height <−2 standard deviations (SD) for sex and chronological age (Wit et al., 2007; Quigley and Ranke, 2016). Microcephaly was defined as head circumference <3rd percentile for sex and chronological age as an approximation to head circumference <−2 SD (Ashwal et al., 2009).

Molecular genetic analysis
Patient A from Family 1 was enrolled in a study for recessive heritable causes of intellectual disability (Abou Jamra et al., 2011) and underwent research whole-exome sequencing (WES), as previously described (Khetarpal et al., 2016). From the same family, Patient B underwent Sanger sequencing to confirm biallelic inheritance of the familial GALNT2 variant identified in Patient A. Patient C from Family 2 had clinical single nucleotide polymorphism (SNP) array performed, which identified several regions of homozygosity. Genes in these regions were subsequently analysed by next-generation sequencing (NGS). Patient D from Family 3 underwent Sanger sequencing to confirm biallelic inheritance of the familial GALNT2 variant identified in Patient E. Patient E, also from Family 3, underwent clinical WES using the NovaSeq 6000 System at the Danish Epilepsy Centre as part of the diagnostic work-up. Research WES was performed for both affected family members in Family 4 (Patients F and G). In this family, WES was performed by using Illumina HiSeq4000, which yields 150-bp paired-end reads covering 85% of the exome at 20× and >96% of the exome at >12×. The GATK best-practices pipeline was used to identify SNP and INDEL variants. Variants were prioritized by minor allele frequency (<0.1% in research exome database of >5000 individuals), conservation and predicted effect on protein function. Variants were confirmed by Sanger sequencing.

ApoC-III isoform analysis
Western blot analysis of plasma apoC-III was performed as previously described (Khetarpal et al., 2016) with minor modifications (Supplementary material). Mass spectrometry analysis of apoC-III isoforms was performed at Mayo Clinic Laboratories (clinical test ID: CDG, Supplementary material).

Galnt2 knockout rodent models
Animal studies were approved by the Institutional Animal Care and Use Committees of the University of Pennsylvania (mice) and SAGE laboratories (rats). Rodents were generated, bred, and genotyped as previously described (Khetarpal et al., 2016). Rodents were subject to alternating 12-h light/dark cycles and given access to standard chow diet ad libitum. Rodents were housed with age- and sex-matched littermate wild-type controls.
at two to four animals per cage. Mouse behavioural testing (Supplementary material) was performed in female mice at 8–10 weeks of age. Investigators were blinded during scoring of behavioural assays.

**Statistical analysis**

Data represent means, with error bars showing ± SDs. Genotype distributions of rodent offspring were analysed by using the χ² test against expected Mendelian distribution. One-way ANOVA with Tukey’s post-test was used to analyse rodent body weight. Two-tailed unpaired Student’s t-test was used to analyse organ weights and data for open-field activities, acoustic startle habituation and prepulse inhibition trials. Two-way repeated measures ANOVA was used to analyse rotarod data (with trial number and genotype as factors), acoustic startle data (with dB and genotype as factors) and olfactory data (with odorant and genotype as factors). Two-way ANOVA with Tukey’s post-test was used to analyse social choice data (with cue type and genotype as factors). Level of significance was set at P ≤ 0.05.

**Data availability**

Data supporting the findings of this study are available from the corresponding author, upon reasonable request.

---

**Results**

**Genetic changes in patients**

Family pedigrees are shown in Fig. 1A. Family histories and GALNT2 genetic changes are shown in Table 1.

Patients A and B (Family 1) were siblings born of consanguineous parents. Both were homozygous for a previously reported pathogenic variant (c.865C>T; p.Gln289*) in GALNT2 (Khetarpal et al., 2016).

In Patient C (Family 2), SNP array identified homozygous inheritance of 11.8 Mb and 2.6 Mb across the 1q41q42.2 and 2q37.3 chromosomal regions, respectively. The only potentially clinically significant homozygous variant identified through clinical NGS of genes in these regions of homozygosity was a homozygous pathogenic variant (c.598C>T; p.Arg200*) in GALNT2. As anticipated, the parents were both confirmed heterozygous for this variant. There was no known parental consanguinity, but the grandfathers were from the same small village. The variant was reported in gnomAD in one heterozygous individual with reference SNP ID rs1431963909.

Patients D and E (Family 3) were siblings who were both homozygous for a novel pathogenic variant (c.296dup;...
p.Tyr99*) in GALNT2. Both parents of the siblings were heterozygous for the GALNT2 variant, although no consanguinity was reported. The variant was absent from control databases (1000 Genomes, ExAC and gnomAD).

Patients F and G (Family 4) were siblings who were both homozygous for a novel missense variant (c.629G>C; p.Arg210Pro) in GALNT2. The consanguineous parents were identified as heterozygous carriers of the variant. The variant was predicted to be disease-causing by MutationTaster and PolyPhen-2 and was absent from control databases (1000 Genomes, ExAC and gnomAD).

### ApoC-III isoform analysis results

Based on our previous studies (Schjoldager et al., 2012; Khetarpal et al., 2016), we analysed plasma apoC-III glycosylation by western blot (Fig. 1B and Supplementary Fig. 1) and mass spectrometry to evaluate and confirm loss-of-function of GALNT2. Western blot analysis of healthy control plasma and standard human apoC-III purified from plasma revealed bands of mono- or disialylated apoC-III<sub>1/2</sub>. Plasma from heterozygous parents showed predominant bands of sialylated apoC-III<sub>1/2</sub>, where patient plasma showed only non-glycosylated apoC-III (apoC-III<sub>0</sub>), which migrated with a reduced molecular weight of 8–9 kDa.

Mass spectrometry analysis was performed using a clinically available test and demonstrated results consistent with western blot analysis, including significantly increased amounts of the non-glycosylated apoC-III isoform (apoC-III<sub>0</sub>) in patient samples (Table 1 and Supplementary Fig. 2). Heterozygous carriers (parents) demonstrated mildly elevated levels of the non-glycosylated apoC-III isoform (apoC-III<sub>0</sub>) (Supplementary Table 1 and Supplementary Fig. 3). Unfortunately, available samples of Family 1 were unacceptable for mass spectrometry analysis and parental samples of Family 2 were unavailable.

The clinical utility of apoC-III as a reliable biomarker of GALNT2 loss-of-function was emphasized by the findings of an additional patient with compound heterozygous missense mutations in GALNT2 but with a dissimilar clinical phenotype (Supplementary material). The western blot analysis demonstrated that this patient had normal levels of sialylated apoC-III<sub>1/2</sub> (Supplementary Fig. 4), indicating that the variants were likely benign and ruling out a diagnosis of GALNT2-CDG.

### Table 1 Family history, GALNT2 genetic changes and apoC-III glycosylation changes in GALNT2-CDG patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Family 1</th>
<th>Family 2</th>
<th>Family 3</th>
<th>Family 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relation</td>
<td>Siblings</td>
<td>–</td>
<td>Siblings</td>
<td>Siblings</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td>Age at last visit</td>
<td>6 months</td>
<td>6 months</td>
<td>4 years</td>
<td>4 months</td>
</tr>
<tr>
<td>Parental descent</td>
<td>Afghan</td>
<td>Italian</td>
<td>Syrian</td>
<td>Egyptian</td>
</tr>
<tr>
<td>Parental consanguinity</td>
<td>First cousins</td>
<td>None known</td>
<td>None known&lt;sup&gt;a&lt;/sup&gt;</td>
<td>First cousins once removed</td>
</tr>
<tr>
<td><strong>GALNT2 genetic changes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amino acid change</td>
<td>p.Gln289&lt;sup&gt;*/&lt;/sup&gt;</td>
<td>p.Gln289&lt;sup&gt;*/&lt;/sup&gt;</td>
<td>p.Arg200&lt;sup&gt;*/&lt;/sup&gt;</td>
<td>p.Tyr99&lt;sup&gt;*/&lt;/sup&gt;</td>
</tr>
<tr>
<td>cDNA change</td>
<td>c.865C&gt;T</td>
<td>c.865C&gt;T</td>
<td>c.598C&gt;T</td>
<td>c.296dup</td>
</tr>
<tr>
<td><strong>ApoC-III western blot</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-glycosylated ApoC-III</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Affininity chromatography-MS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ApoC-III/apoC-III&lt;sub&gt;1&lt;/sub&gt; ratio</td>
<td>Not performed</td>
<td>Not performed</td>
<td>2.63 (&lt;2.91)</td>
<td>1.35 (&lt;2.91)</td>
</tr>
<tr>
<td>ApoC-III&lt;sub&gt;0&lt;/sub&gt;/apoC-III&lt;sub&gt;2&lt;/sub&gt; ratio</td>
<td>Not performed</td>
<td>Not performed</td>
<td>23.87 (&lt;4.8)</td>
<td>15.56 (&lt;4.8)</td>
</tr>
<tr>
<td>Transferrin mono-oligo/di-oligo ratio</td>
<td>Not performed</td>
<td>Not performed</td>
<td>0.060 (&lt;0.06)</td>
<td>0.063 (&lt;0.06)</td>
</tr>
<tr>
<td>Transferrin a-oligo/di-oligo ratio</td>
<td>Not performed</td>
<td>Not performed</td>
<td>0.004 (&lt;0.01)</td>
<td>0.004 (&lt;0.01)</td>
</tr>
<tr>
<td>Transferrin tri-sialo/di-oligo ratio</td>
<td>Not performed</td>
<td>Not performed</td>
<td>0.07 (&lt;0.05)</td>
<td>0.038 (&lt;0.05)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Both grandfathers are from same village (~2000 inhabitants).

<sup>b</sup> Parents are both from the Aleppo area in Syria.

WT = wild-type.
Table 2 Clinical characterization, blood test results, brain MRI scans and other paraclinical findings in GALNT2-CDG patients

<table>
<thead>
<tr>
<th></th>
<th>Patient A</th>
<th>Patient B</th>
<th>Patient C</th>
<th>Patient D</th>
<th>Patient E</th>
<th>Patient F</th>
<th>Patient G</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth length, m</td>
<td>0.46 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.48 (p15-p25)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.45 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
</tr>
<tr>
<td>Birth weight, kg</td>
<td>2.49 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.86 (p5-p15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.3 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.5 (p5)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.0 (p95)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.00 (p25-p50)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.20 (p50)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Head circumference at birth, cm</td>
<td>Not reported</td>
<td>33.0 (p5-p15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>33.0 (p15-p25)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
<td>Reportedly normal</td>
</tr>
<tr>
<td>Age at last measurement</td>
<td>9 y 0 mo</td>
<td>6 y 3 mo</td>
<td>4 y 4 mo</td>
<td>20 y 10 mo</td>
<td>13 y 8 mo</td>
<td>13 y 5 mo</td>
<td>10 y 10 mo</td>
</tr>
<tr>
<td>Height at last measurement, m</td>
<td>1.27 (p15-p25)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.16 (p15-p25)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.98 (p5-p15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.45 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.45 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.48 (p5-p15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.29 (&lt; -2 SD)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Weight at last measurement, kg</td>
<td>27.0 (p25-p50)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>20.0 (p25-p50)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>14.1 (p5-p15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>45.5 (p3-p10)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>43.5 (p10-p25)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>57.0 (p75-p90)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>45.0 (p75-p90)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Head circumference at last measurement, cm</td>
<td>51.5 (p10-p25)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>51.5 (p25-p50)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>47.0 (p3-p15)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>51.1 (&lt; p3)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>52.0 (p3-p10)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>55.5 (p90-p97)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>54.0 (p75-p90)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Microcephaly</strong></td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Psychomotor development</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross motor delay</td>
<td>Severe</td>
<td>Severe</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Sitting age; age of independent walking</td>
<td>12 mo; 6 y</td>
<td>18 mo; 6 y</td>
<td>21 mo; 3 y</td>
<td>8 mo; 2 y</td>
<td>8 mo; 2 y</td>
<td>7 mo; 13 mo</td>
<td>7 mo; 15 mo</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
<td>Moderate–severe</td>
<td>Severe</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>Understands commands</td>
<td>Few commands</td>
<td>Few commands</td>
<td>Almost absent</td>
<td>Good understanding</td>
<td>Few commands</td>
<td>Good understanding</td>
<td>Several commands</td>
</tr>
<tr>
<td>Expressive speech</td>
<td>Few words</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td>Yes; loss of words</td>
<td>Yes; loss of words</td>
</tr>
<tr>
<td>Loss of psychomotor function</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Neurological</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye contact</td>
<td>Poor</td>
<td>Poor</td>
<td>Poor</td>
<td>Good</td>
<td>Poor</td>
<td>Average</td>
<td>Poor</td>
</tr>
<tr>
<td>Autistic behaviour</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Behavioural problems</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Epilepsy; age of onset</td>
<td>Yes; 2.5 y</td>
<td>Yes; 2.5 y</td>
<td>Yes; 4 mo</td>
<td>Yes; 1 year</td>
<td>Yes; 1.5 y</td>
<td>No</td>
<td>Yes; 4 y</td>
</tr>
<tr>
<td>Type of epilepsy, EEG</td>
<td>Multifocal</td>
<td>Multifocal</td>
<td>Infantile spasms</td>
<td>Multifocal, eye-closure sensitivity</td>
<td>Multifocal, eye-closure sensitivity</td>
<td>N/A</td>
<td>Head drops</td>
</tr>
<tr>
<td>Current epilepsy status</td>
<td>Seizure-free on meds</td>
<td>Treatment-resistant</td>
<td>Seizure-free on meds</td>
<td>Treatment-resistant</td>
<td>Treatment-resistant</td>
<td>N/A</td>
<td>Restarted on medication</td>
</tr>
<tr>
<td>Sleeping problems</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
</tr>
<tr>
<td>Vision, eye examination</td>
<td>Alternating strabismus</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
<td>Chronic insomnia</td>
</tr>
<tr>
<td>Hearing</td>
<td>Perceived as normal</td>
<td>Perceived as normal</td>
<td>Bilateral conductive hearing loss</td>
<td>Perceived as normal</td>
<td>Perceived as normal</td>
<td>Perceived as normal</td>
<td>Perceived as normal</td>
</tr>
<tr>
<td><strong>Blood tests</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>124&lt;sup&gt;d&lt;/sup&gt;</td>
<td>ND</td>
<td>148 (120–200)</td>
<td>85 (&lt; 193)</td>
<td>124 (&lt; 193)</td>
<td>161 (70–200)</td>
<td>139 (70–200)</td>
</tr>
<tr>
<td>HDL-cholesterol, mg/dl</td>
<td>27&lt;sup&gt;d&lt;/sup&gt;</td>
<td>ND</td>
<td>34 (&gt; 30)</td>
<td>43 (&lt; 39)</td>
<td>25 (&lt; 39)</td>
<td>41 (35–65)</td>
<td>38 (35–65)</td>
</tr>
<tr>
<td>LDL-cholesterol, mg/dl</td>
<td>51&lt;sup&gt;d&lt;/sup&gt;</td>
<td>ND</td>
<td>98 (50–150)</td>
<td>31 (&lt; 116)</td>
<td>81 (&lt; 116)</td>
<td>108 (70–135)</td>
<td>76 (70–135)</td>
</tr>
<tr>
<td>Triglyceride, mg/dl</td>
<td>93&lt;sup&gt;d&lt;/sup&gt;</td>
<td>ND</td>
<td>99 (40–150)</td>
<td>68 (&lt; 177)</td>
<td>76 (&lt; 177)</td>
<td>57 (35–135)</td>
<td>124 (35–135)</td>
</tr>
<tr>
<td>Creatinine, mg/dl</td>
<td>0.28 (0.53–0.79)</td>
<td>0.31 (0.40–0.60)</td>
<td>0.23 (0.20–0.90)</td>
<td>0.41 (0.57–1.02)</td>
<td>0.53 (0.59–1.05)</td>
<td>0.49 (0.5–1.1)</td>
<td>0.42 (0.5–1.0)</td>
</tr>
<tr>
<td>Findings</td>
<td>WML, brachycephaly</td>
<td>WML, brachycephaly</td>
<td>WML; regional myelin-formation arrest; small pineal cyst; microcephaly</td>
<td>WML; mild cerebellar atrophy; thickened calvarium; microcephaly</td>
<td>WML</td>
<td>Discrete WML; persisting cavum septum Pellucidum with cavum vergae</td>
<td>No WML; small pineal cyst</td>
</tr>
</tbody>
</table>

GGT = gamma-glutamyltransferase; IDA = iron deficiency anaemia; NA = not applicable; ND = not determined; p = percentile; WML = white matter lesions. See Supplementary Table 2 for a full version of this table.

Growth charts:<sup>a</sup>WHO growth charts;<sup>b</sup>Centers for Disease Control and Prevention (CDC) Growth Charts;<sup>c</sup>Rollins et al. (2010). United States Head Circumference Growth Reference Charts: Birth to 21 Years.
<sup>d</sup>Reported by Khetarpal et al. (2016).
<sup>e</sup>For blood test results, ‘Normal’ refers to results within the reference interval of the parameter.
<sup>f</sup>Corrected with iron supplementation.
Clinical characteristics

Patient clinical characteristics are summarized in Table 2 and Supplementary Table 2. For details of individual patients, see the Supplementary material. For patient photographs and dysmorphic facial features, see Fig. 2.

Growth

All patient heights were < 25th percentile, and three patients had short stature (< −2 SD). In Patient E, bone age was found to be the same as chronological age. Two patients had microcephaly.
Dysmorphic facial features

All patients exhibited some degree of dysmorphic facial features (Fig. 2), commonly including elongated face, high forehead, almond-shaped eyes, protruding maxilla, short philtrum, low-set, posteriorly rotated ears and frequently full lips with a tented or curved upper lip.

Psychomotor developmental delay and autistic features

All seven patients demonstrated delays in psychomotor development. Five of seven patients were delayed in gross motor function with age for independent walking between 2 years and 6 years. Patients F and G walked independently at age 13 months and 15 months, respectively. All patients had varying degrees of language deficits with the ability to understand commands extending from good (Patients D and F) to almost absent. Expressive speech was absent for five patients, while two patients were capable of saying a few words (Patients A and F).

Formal testing for autism spectrum disorder was not performed; however, six patients displayed autistic behaviours (i.e. lack of interest in others, delayed language development and stereotypical movements and behaviour). Three patients had loss of a few words at 2 years of age, but loss of psychomotor function was otherwise not seen in this patient group.

Epilepsy

Six patients had epilepsy of varying types and severities. The remaining patient (Patient F) was treated for suspected epilepsy after a febrile seizure at age 1 year, but the diagnosis was later dismissed (Supplementary material). Patient C had infantile spasms starting at 4 months of age and was seizure-free with treatment by 12 months. Four patients had onset of multifocal epilepsy with various seizure types beginning at 1–2.5 years. In three of these patients, epilepsy was treatment-resistant. One patient (Patient G) had epileptic drop attacks of the head beginning at 4 years that were successfully treated with ethosuximide.

Sleep disturbances

Sleep disturbance was a prominent feature in this patient group. Six patients had chronic insomnia with problems falling asleep, sleep disruption and daytime tiredness or sleepiness at least three times a week for the last 3 months (Pradeep et al., 2019). In all of the six patients the chronic insomnia was of years duration. Melatonin therapy improved the insomnia in four patients, and had no effect in two patients (Supplementary material). Sleep study showed parasomnias in one patient (Patient B). In Patient E, disrupted sleep was partly due to night-time seizures documented during long-term video-EEG monitoring, but awakenings were also seen, when no seizures were registered (EEG results not shown).

Brain MRI findings

Brain MRI scans were obtained using various protocols for all seven patients at various ages (Fig. 3). For detailed descriptions of brain MRI scans, see the Supplementary material. White matter lesions were observed on scans of six of the seven patients (Table 2 and Supplementary Table 2), but varied in their patterns and locations among patients.

Laboratory findings

Blood test results are summarized in Table 2 and Supplementary Table 2 with reference intervals as stated by the performing local laboratory. Patient A was previously reported to have a fasting lipid profile with HDL-C level below the fifth percentile and a moderately low triglyceride level (Khetarpal et al., 2016). Lower HDL-C levels were seen in five other patients; Patient E had HDL-C level below the reference interval, and four patients had HDL-C levels just above the lower level of the reference interval. The lipid profile for Patient B was not examined. Fasting triglyceride levels ranged from low (Patients D–F) to high in the reference interval (Patient G). Four patients had iron-deficiency anaemia with low haemoglobin and ferritin levels corrected with iron supplementation. White blood cell counts and platelet counts as well as bilirubin and thyroid parameters were normal in all patients. Six patients had low vitamin D levels corrected with vitamin D supplementation. The patients showed decreased levels of serum creatinine.

GALNT2-CDG rodent models

Physical parameters

Given the multisystem involvement of GALNT2-CDG patients, we pursued further characterization of germline Galnt2 knockout rodent models of GALNT2-CDG (Khetarpal et al., 2016). Significant embryonic lethality occurred in both rodent knockout models (Supplementary material). In surviving animals we observed decreased body weight in male knockout mice \( F(2,66) = 11.27, \ P = 6.2 \times 10^{-5}; \text{Fig. 4B} \), female knockout rats \( F(2,20) = 4.60, \ P = 0.02; \text{Fig. 4C} \) and male knockout rats \( F(2,21) = 11.91, \ P = 0.0003; \text{Fig. 4D} \). We also observed mildly increased liver weights in knockout mice (Supplementary Fig. 5A). Additionally, knockout rodents had abnormal craniofacial features with decreased snout length (Fig. 4E and F).

Behavioural phenotypes

Analysis of spontaneous open field activity showed increased centre \( t(1,25) = 3.21, \ P = 0.004; \text{Supplementary Fig. 6B} \) and rearing activities \( t(1,25) = 3.394, \ P = 0.002; \text{Supplementary Fig. 6C} \) of Galnt2 knockout compared to wild-type littermates with normal horizontal activity \( t(1,25) = 0.43, \ P = 0.67; \text{Supplementary Fig. 6A} \). On accelerating rotorad testing, knockout mice showed reduced latency to fall \( F(1,28) = 11.06, \ P = 0.002; \text{Fig. 5A} \). On acoustic startle response and prepulse inhibition testing, knockout mice...
showed potentiated habituation to acoustic stimuli \( t(1,27) = 2.18, P = 0.04 \); Fig. 5B] and disrupted prepulse inhibition \( t(1,27) = 2.02, P = 0.05 \); Fig. 5C] with similar responses to increases in acoustic stimulus intensities \( F(1,27) = 1.95, P = 0.17 \); Supplementary Fig. 6D). On social preference testing, Galnt2 knockout mice showing reduced exploration of the social cue \( F(1,44) = 7.87, P = 0.007 \); Fig. 5D], with intact olfaction \( F(3,46) = 9.85, P = 3.9 \times 10^{-5} \); Supplementary Fig. 7], the primary sensory mediator of murine social behaviour.

Discussion

Here, we describe seven patients with a novel autosomal recessive congenital disorder of O-glycosylation, GALNT2-CDG, and validate plasma apoC-III as a biomarker of the disease. Clinically GALNT2-CDG patients demonstrated global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, decreased stature, and white matter lesions on brain MRI scan. GALNT2-CDG patients

![Figure 3 Brain MRI results obtained from seven GALNT2-CDG patients at different ages. MRI scans showed white matter lesions in scans from Patients A–F but not in scan from Patient G. Patient age at the time of the MRI scan is shown. Columns 1 and 2 depict axial FLAIR images (or coronal FLAIR for Patient A at 35 months, Patient B, and Patient F). Column 3 depicts T2-weighted images in axial view (or coronal view for Patients C–E). Column 4 depicts sagittal T1-weighted images (with intravenous contrast for Patient A at 35 months and Patient B).]
also had some dysmorphic facial features in common though not comprising a recognizable dysmorphic facial phenotype. Because of their clinical variability, directly diagnosing GALNT2-CDG in patients with developmental delay is challenging. In patients with developmental delay, the presence of dysmorphic features, epilepsy appearing in the first years of life, and brain MRI abnormalities make a genetic aetiology likely. In such patients, coinciding decreased growth or short stature, white matter lesions on brain MRI, and decreased HDL-C would particularly suggest consideration of GALNT2-CDG. Hence, clinical work-up suggested would be a comprehensive history including family history and consanguinity, physical examination, growth chart evaluation, blood chemistry including fasting lipid levels, EEG, brain MRI scan, evaluation of vision and hearing, and genetic testing with WES.

Validating pathogenic variants in glycosyltransferase genes, such as GALNT2, is difficult. Prediction algorithms perform poorly for these genes (Hansen et al., 2015), and labour-intensive experimental assays may be prone to uncertainties (Guda et al., 2009). To aid in interpretation of GALNT2 variants identified in NGS or WES studies, we validated complete loss of O-glycans on the abundant plasma apoC-III O-glycoprotein as a diagnostic assay of GALNT2-CDG. Highlighting the clinical utility of the assay, an eighth patient with a dissimilar clinical presentation and compound heterozygous variants in GALNT2 had normal apoC-III glycosylation, which ruled out GALNT2 deficiency.

GALNT2 polymorphisms were first associated with plasma lipids in GWAS (Kathiresan et al., 2008), and GALNT2 loss-of-function was later confirmed to decrease HDL-C levels in rodent knockout models (Khetarpal et al., 2016). All patients with available fasting lipid profiles had lower plasma HDL-C levels, consistent with previous findings (Khetarpal et al., 2016).

Rodent Galnt2 knockout models recapitulated clinical features of GALNT2-CDG patients, including growth differences, abnormal craniofacial morphology, and neurodevelopmental anomalies. The observed deficits in coordination, sensory-motor integration, and sociability suggest that multiple neurological pathways are altered in Galnt2-deficient models, potentially including dopamine-dependent (Karasinska et al., 2000), GABAergic (Liu et al., 2007) and serotoninergic (Kelley et al., 2003) pathways. Our rodents are limited as models of GALNT2-CDG because of significant embryonic lethality and the clinical heterogeneity of GALNT2-CDG patients. However, shared neurodevelopmental abnormalities suggest that important insights will come from further studies of the roles of GALNT2 in the developing brain.
The high prevalence of neurological disease among CDG patients highlights the brain’s dependence on various glycosylation types. Deficiencies in several glycosylation pathways, including GalNAc-type O-glycosylation, can cause epilepsy ranging in severity from easily controlled to severe epileptic encephalopathy (Morava et al., 2012; Arranz et al., 2014). Glycosylation deficiency can also result in brain MRI white matter lesion changes as seen in GALNT2-CDG, which were non-specific and without a shared neuroimaging pattern. Non-specific white matter lesions have been reported in other CDG types, such as dystroglycanopathies and SLC35A2-CDG. These CDGs involve distinct glycosylation types from the GalNAc-type glycosylation in GALNT2-CDG. Dystroglycanopathies result from mutations in glycosyltransferase enzyme genes involved in O-mannosylation (Clement et al., 2008) and SLC35A2-CDG is a disorder of N-linked glycosylation (Vals et al., 2019).

GALNT2-CDG patients suffer from multisystemic disease manifestations, suggesting non-redundant functions of GALNT2 beyond the previously identified specific glycosylation of proteins involved in lipid metabolism, including ANGPTL3, apoC-III and PLTP. Deficient O-glycosylation of PLTP reduces phospholipid transfer to HDL and lowers HDL-C levels (Khetarpal et al., 2016); however, PLTP is broadly expressed throughout the body, including by neurons and glial cells in the brain (Vuletic et al., 2003) potentially influencing neuro-pathogenesis in GALNT2-CDG patients. GALNT2 is ubiquitously expressed in all mammalian cells and tissues and the function of GALNT2 will depend on the available substrates and repertoire of other GALNT isoenzymes expressed in a given cell. In most cells and tissues analysed so far, GALNT2 has only a minor non-redundant, isoform-specific contribution to the O-glycoproteome (Schjoldager et al., 2015; Khetarpal et al., 2016). Thus, the GALNT2-CDG disease pathophysiology likely involves deficient GALNT2 O-glycosylation on a subset of target glycoproteins. Additional studies to identify the protein substrates of GALNT2 will reveal important insights into the pathophysiology and phenotypes of GALNT2-CDG, as well as the critical role of O-glycosylation in the normal function of substrate proteins, particularly in neurodevelopmental biology.

Figure 4 Growth parameters of GALNT2-CDG rodent models. Bar plots of the mean body weight of wild-type (WT), Galnt2$^{+/−}$ heterozygous (Het), and Galnt2$^{−/−}$ (KO) rodents are shown for (A) female mice, (B) male mice, (C) female rats, and (D) male rats. Representative pictures of wild-type and knockout (E) mice and (F) rats are shown. Error bars represent standard deviation. Significant $P$-values from Tukey’s post-test are indicated. Number of animals is indicated in parenthesis.
Acknowledgements

We would like to thank the families for their participation in this study. We thank the Broad Institute (HG008900 to Daniel MacArthur and Heidi Rehm). Mouse behavioural phenotyping was performed at the Neurobehavior Testing Core at the University of Pennsylvania/ITMAT and IDDRC at the Children’s Hospital of Philadelphia/Penn U54 HD086984. We thank Dr Zhaolan Zhou for his helpful guidance with the manuscript and Dr Kathryn Kadash for her critical review of the manuscript.

Funding

This work was supported by the Foundation Leducq CVGeneF(x) Transatlantic Network of Excellence grant to D.J.R., supported by the Magnus Ehrnrooth Foundation to U.P.R., by National Institutes of Health grants F30HL124967 to S.A.K., T32 GM008638 to A.C.E., and U54 NS115198 to A.C.E. and K.R., and by the Danish National Research Foundation (DNRF107) and a Novo Nordisk Foundation Excellence grant to K.S.

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at Brain online.

References


Ng BG, Freeze HH, Perspectives on glycosylation and its congenital disorders. Trends Genet 2018; 34: 466–76.


